Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study
Arterial spin labelling (ASL) enables non-invasive quantification of regional brain perfusion using MRI. ASL was used in the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) multi-centre trial to pilot the assessment of the effects of the anti-hypertension drug lo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Cerebral Circulation - Cognition and Behavior |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666245024001776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545521657806848 |
|---|---|
| author | Lina Jarutyte Jan Petr Nicholas Turner Patrick G. Kehoe Henk-Jan Mutsaerts David L. Thomas |
| author_facet | Lina Jarutyte Jan Petr Nicholas Turner Patrick G. Kehoe Henk-Jan Mutsaerts David L. Thomas |
| author_sort | Lina Jarutyte |
| collection | DOAJ |
| description | Arterial spin labelling (ASL) enables non-invasive quantification of regional brain perfusion using MRI. ASL was used in the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) multi-centre trial to pilot the assessment of the effects of the anti-hypertension drug losartan on cerebral blood flow (CBF). In the multi-centre setting, disparities in ASL implementation on scanners from different manufacturers lead to inherent differences in measured CBF and its associated parameters (e.g. spatial coefficient of variation (sCoV) of CBF, a proxy of arterial arrival times). In addition, differences in ASL acquisition parameter settings can also affect the measured quantitative perfusion values. In this study, we used data from the RADAR cohort as a case study to evaluate the site-dependent systematic differences of CBF and sCoV, and show that variations in the readout module (2D or 3D) and the post-labelling delay acquisition parameter introduced artifactual group differences. When accounting for this effect in data analysis, we show that it is still possible to combine ASL data across sites to observe the expected relationships between grey matter CBF and cognitive scores. In summary, ASL can provide useful information relating to CBF difference in multi-centre therapeutic trials, but care must be taken in data analysis to account for the inevitable inter-site differences in scanner type and acquisition protocol. |
| format | Article |
| id | doaj-art-90164ecb4b504637a1d5cec99c180167 |
| institution | Kabale University |
| issn | 2666-2450 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cerebral Circulation - Cognition and Behavior |
| spelling | doaj-art-90164ecb4b504637a1d5cec99c1801672025-01-12T05:25:48ZengElsevierCerebral Circulation - Cognition and Behavior2666-24502025-01-018100376Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR studyLina Jarutyte0Jan Petr1Nicholas Turner2Patrick G. Kehoe3Henk-Jan Mutsaerts4David L. Thomas5School of Psychological Science, University of Bristol, Bristol, UK; Nuffield Department of Population Health, University of Oxford, Oxford, UKHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GermanyBristol Medical School, University of Bristol, Bristol, UKBristol Medical School, University of Bristol, Bristol, UK; Elizabeth Blackwell Institute for Health Research, University of Bristol; Corresponding author at: Bristol Medical School, Level 2 Learning and Research Building, Southmead Hospital. Bristol, BS10 5NB, UK.Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, the NetherlandsDepartment of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UKArterial spin labelling (ASL) enables non-invasive quantification of regional brain perfusion using MRI. ASL was used in the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) multi-centre trial to pilot the assessment of the effects of the anti-hypertension drug losartan on cerebral blood flow (CBF). In the multi-centre setting, disparities in ASL implementation on scanners from different manufacturers lead to inherent differences in measured CBF and its associated parameters (e.g. spatial coefficient of variation (sCoV) of CBF, a proxy of arterial arrival times). In addition, differences in ASL acquisition parameter settings can also affect the measured quantitative perfusion values. In this study, we used data from the RADAR cohort as a case study to evaluate the site-dependent systematic differences of CBF and sCoV, and show that variations in the readout module (2D or 3D) and the post-labelling delay acquisition parameter introduced artifactual group differences. When accounting for this effect in data analysis, we show that it is still possible to combine ASL data across sites to observe the expected relationships between grey matter CBF and cognitive scores. In summary, ASL can provide useful information relating to CBF difference in multi-centre therapeutic trials, but care must be taken in data analysis to account for the inevitable inter-site differences in scanner type and acquisition protocol.http://www.sciencedirect.com/science/article/pii/S2666245024001776Cerebral blood flowArterial spin labellingMRIMulti-centre randomised controlled trialsAlzheimer's diseaseHypertension |
| spellingShingle | Lina Jarutyte Jan Petr Nicholas Turner Patrick G. Kehoe Henk-Jan Mutsaerts David L. Thomas Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study Cerebral Circulation - Cognition and Behavior Cerebral blood flow Arterial spin labelling MRI Multi-centre randomised controlled trials Alzheimer's disease Hypertension |
| title | Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study |
| title_full | Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study |
| title_fullStr | Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study |
| title_full_unstemmed | Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study |
| title_short | Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study |
| title_sort | advantages and challenges of using arterial spin labelling mri to monitor cerebral blood flow in multi centre clinical trials of neurodegenerative disease experience from the radar study |
| topic | Cerebral blood flow Arterial spin labelling MRI Multi-centre randomised controlled trials Alzheimer's disease Hypertension |
| url | http://www.sciencedirect.com/science/article/pii/S2666245024001776 |
| work_keys_str_mv | AT linajarutyte advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy AT janpetr advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy AT nicholasturner advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy AT patrickgkehoe advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy AT henkjanmutsaerts advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy AT davidlthomas advantagesandchallengesofusingarterialspinlabellingmritomonitorcerebralbloodflowinmulticentreclinicaltrialsofneurodegenerativediseaseexperiencefromtheradarstudy |